Biogen admits slow Aduhelm launch, as scientists question label again
pharmaphorum
SEPTEMBER 10, 2021
.” He blamed the poor performance on ” confusion, misinformation and controversy surrounding our data and the approval process.” “Our findings are concerning given the broad FDA labelling for aducanumab,” said corresponding author Timothy Anderson.
Let's personalize your content